Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DeLLphi-301: Phase 2 Study of Tarlatamab in Relapsed/Refractory Small Cell Lung Cancer
jRCT2061210077Phase 2Active, not recruiting
- Sponsor
- Amgen
- Start
- Dec 2021
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label trial of tarlatamab in small cell lung cancer (SCLC) (4 arms), sponsored by Amgen. Primary endpoints: Objective Response (OR) per RECIST 1.1 by Investigator (Part 1), Number of Participants with Treatment-emergent Adverse Events (Part 1 and Part 3) and 2 more. Started Dec 2021; status: active, not recruiting.
02
Drugs
tarlatamab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on jRCT2061210077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061210077.